These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 37870697)

  • 1. Advances in the Management of Recurrent Cervical Cancer: State of the Art and Future Perspectives.
    Giudice E; Mirza MR; Lorusso D
    Curr Oncol Rep; 2023 Nov; 25(11):1307-1326. PubMed ID: 37870697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted treatment options for the management of metastatic/persistent and recurrent cervical cancer.
    Mutlu L; Tymon-Rosario J; Harold J; Menderes G
    Expert Rev Anticancer Ther; 2022 Jun; 22(6):633-645. PubMed ID: 35533682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review.
    Boussios S; Seraj E; Zarkavelis G; Petrakis D; Kollas A; Kafantari A; Assi A; Tatsi K; Pavlidis N; Pentheroudakis G
    Crit Rev Oncol Hematol; 2016 Dec; 108():164-174. PubMed ID: 27931835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline?
    Vergote I; Ray-Coquard I; Lorusso D; Oaknin A; Cibula D; Van Gorp T
    Expert Opin Investig Drugs; 2023 Mar; 32(3):201-211. PubMed ID: 36803278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of metastatic urothelial carcinoma: Current approach, emerging agents, and future perspectives.
    Iacovelli R; Cicala CM; Ciccarese C; Sacco E; Racioppi M; Bassi PF; Tortora G
    Urologia; 2023 Feb; 90(1):3-10. PubMed ID: 36537831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The abscopal effect of immune-radiation therapy in recurrent and metastatic cervical cancer: a narrative review.
    Ollivier L; Moreau Bachelard C; Renaud E; Dhamelincourt E; Lucia F
    Front Immunol; 2023; 14():1201675. PubMed ID: 37539054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IMMUNOTHERAPY TREATMENT AGAINST CERVICAL CANCER.
    Jiménez-Lima R; Arango-Bravo E; Galicia-Carmona T; Lino-Silva LS; Trejo-Durán GE; Alvarado-Silva C; Castañeda-Renderos OH; Vanoye-Carlo EG; Torre CF; Dueñas-González A; Cetina-Pérez L
    Rev Invest Clin; 2020; 72(4):231-238. PubMed ID: 33064705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Balstilimab and other immunotherapy for recurrent and metastatic cervical cancer.
    Bose CK
    Med Oncol; 2022 Jan; 39(4):47. PubMed ID: 35092506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond Platinum, ICIs in Metastatic Cervical Cancer: A Systematic Review.
    Maiorano BA; Maiorano MFP; Ciardiello D; Maglione A; Orditura M; Lorusso D; Maiello E
    Cancers (Basel); 2022 Dec; 14(23):. PubMed ID: 36497437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer.
    O'Malley DM; Oaknin A; Monk BJ; Selle F; Rojas C; Gladieff L; Berton D; Leary A; Moore KN; Estevez-Diz MDP; Hardy-Bessard AC; Alexandre J; Opperman CP; de Azevedo CRAS; Randall LM; Feliu WO; Ancukiewicz M; Ray-Coquard I
    Gynecol Oncol; 2021 Nov; 163(2):274-280. PubMed ID: 34452745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent or primary metastatic cervical cancer: current and future treatments.
    Gennigens C; Jerusalem G; Lapaille L; De Cuypere M; Streel S; Kridelka F; Ray-Coquard I
    ESMO Open; 2022 Oct; 7(5):100579. PubMed ID: 36108558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials.
    Monk BJ; Enomoto T; Kast WM; McCormack M; Tan DSP; Wu X; González-Martín A
    Cancer Treat Rev; 2022 May; 106():102385. PubMed ID: 35413489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Both combined or sequential use with immune checkpoint inhibitors on cetuximab-treated patients with recurrent or metastatic head and neck squamous cell carcinoma improve the overall survival.
    Lien MY; Wang TH; Hsieh CY; Tsai MH; Hua CH; Cheng FM; Chung WH; Tang CH; Chia-Hsun Hsieh J
    Oral Oncol; 2021 Aug; 119():105380. PubMed ID: 34146822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint inhibitors in advanced and recurrent/metastatic cervical cancer.
    Han X; Chang WW; Xia X
    Front Oncol; 2022; 12():996495. PubMed ID: 36276090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer.
    Melosky B; Cheema PK; Brade A; McLeod D; Liu G; Price PW; Jao K; Schellenberg DD; Juergens R; Leighl N; Chu Q
    Oncologist; 2020 Nov; 25(11):981-992. PubMed ID: 32860288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacotherapy for the treatment of recurrent cervical cancer: an update of the literature.
    D'Oria O; Bogani G; Cuccu I; D'Auge TG; Di Donato V; Caserta D; Giannini A
    Expert Opin Pharmacother; 2024; 25(1):55-65. PubMed ID: 38159033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolving standards and future directions for systemic therapies in cervical cancer.
    Ang DJM; Chan JJ
    J Gynecol Oncol; 2024 Mar; 35(2):e65. PubMed ID: 38282261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in immunotherapy for cervical cancer: recent developments and future directions.
    Sherer MV; Kotha NV; Williamson C; Mayadev J
    Int J Gynecol Cancer; 2022 Mar; 32(3):281-287. PubMed ID: 35256414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in immunotherapy in cervical cancer.
    Grau JF; Farinas-Madrid L; Garcia-Duran C; Garcia-Illescas D; Oaknin A
    Int J Gynecol Cancer; 2023 Mar; 33(3):403-413. PubMed ID: 36878562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.